GeNeuro announced a collaboration with Verily to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. Through this collaboration, GeNeuro will partner with Verily to build on results published earlier this year in Cell Press, which evidenced the in vitro activation of HERV-W by SARS-CoV- 2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with COVID-19 severity. Verily will provide high-resolution multi-omic data generated from COVID patient samples using Immune Profiler, Verily's immune mapping platform, and high-powered data analysis using Workbench, a secure research environment for governing and analyzing multimodal biomedical data.

Both solutions are part of Verily's broader suite of products built to deliver on the promise of precision health and harness the power of richer, more diverse datasets to accelerate medical research.